Benefits versus risk profile of buparlisib for the treatment of breast cancer-Reference-Cited by-同舟云学术

Benefits versus risk profile of buparlisib for the treatment of breast cancer

Published:2019-06-17 Issue:7 Volume:18 Page:553-562
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Patsouris Anne¹,Augereau Paule²,Frenel Jean-Sebastien²,Robert Marie²,Gourmelon Carole²,Bourbouloux Emmanuelle²,Berton-Rigaud Dominque²,Chevalier Louise-Marie³,Campone Mario⁴

Affiliation:

1. Unité INSERM 1232, Equipe 12, CRCINA, ICO Nantes-Angers, Nantes, France

2. Departement of medical oncology, ICO Nantes-Angers, Nantes, France

3. Department of Genomic, ICO Nantes-Angers, Nantes, France

4. Unité INSERM 1232, Equipe 8 CRCINA, ICO Nantes-Angers, Nantes, France

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2019.1623877

Reference46 articles.

1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

3. Targeting PI3K signalling in cancer: opportunities, challenges and limitations

4. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?;Clinical Drug Investigation;2023-11-17

2. Synergistic effects of inhibitors targeting PI3K and Aurora Kinase A in preclinical inflammatory breast cancer models;2023-08-13

3. BKM120 alters the migration of doublecortin-positive cells in the dentate gyrus of mice;Pharmacological Research;2022-05

4. Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors;Journal of Biomolecular Structure and Dynamics;2021-12-16

5. PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance;Critical Reviews in Oncology/Hematology;2021-06